Efficacy of Vandetanib in Treating Locally Advanced or Metastatic Medullary Thyroid Carcinoma According to RECIST Criteria: A Systematic Review and Meta-Analysis
BackgroundVandetanib is the most largely used tyrosine kinase inhibitor (TKI) in patients with locally advanced and/or metastatic medullary thyroid cancer (MTC). Here, we conducted a systematic review on its efficacy and attempted to perform a meta-analysis adopting standardized RECIST criteria as e...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2018-05-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/article/10.3389/fendo.2018.00224/full |
| _version_ | 1811242170977353728 |
|---|---|
| author | Pierpaolo Trimboli Marco Castellana Camilla Virili Francesco Giorgino Luca Giovanella |
| author_facet | Pierpaolo Trimboli Marco Castellana Camilla Virili Francesco Giorgino Luca Giovanella |
| author_sort | Pierpaolo Trimboli |
| collection | DOAJ |
| description | BackgroundVandetanib is the most largely used tyrosine kinase inhibitor (TKI) in patients with locally advanced and/or metastatic medullary thyroid cancer (MTC). Here, we conducted a systematic review on its efficacy and attempted to perform a meta-analysis adopting standardized RECIST criteria as end-points.MethodsThe terms “medullary thyroid” and “protein kinase inhibitor” (then including all TKIs) were searched in PubMed, ClinicalTrials.gov, and CENTRAL. Only original studies reporting the use of Vandetanib as single agent in MTC were included. The last search was performed on October 31, 2017 and registered in PROSPERO on December 12, 2017 (n = CRD42017081537).ResultsThe search revealed 487 articles, and, after removing duplicates, reading title and abstract, and screening the eligible papers, 10 studied were finally included. Two papers were randomized controlled trials and eight were observational longitudinal studies. No data were available for overall survival. No heterogeneity nor publication bias were recorded in the pooled rate of complete response (0.7%) and stable disease (47%). Mild to moderate heterogeneity were recorded in the pooled rate of other endpoints. Data of the studies did not allow to perform a meta-analysis of time-to-event outcomes.ConclusionVandetanib should be considered as a promising treatment in advanced MTC. However, data based on RECIST endpoints do not currently provide high-level evidence on its efficacy. |
| first_indexed | 2024-04-12T13:47:52Z |
| format | Article |
| id | doaj.art-db12174b59274bbcb97404522b5aba8a |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-04-12T13:47:52Z |
| publishDate | 2018-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-db12174b59274bbcb97404522b5aba8a2022-12-22T03:30:37ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922018-05-01910.3389/fendo.2018.00224374193Efficacy of Vandetanib in Treating Locally Advanced or Metastatic Medullary Thyroid Carcinoma According to RECIST Criteria: A Systematic Review and Meta-AnalysisPierpaolo Trimboli0Marco Castellana1Camilla Virili2Francesco Giorgino3Luca Giovanella4Department of Nuclear Medicine and Thyroid Centre, Oncology Institute of Southern Switzerland, Bellinzona, SwitzerlandDepartment of Emergency and Organ Transplantation, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, ItalyDepartment of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, ItalyDepartment of Emergency and Organ Transplantation, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, ItalyDepartment of Nuclear Medicine and Thyroid Centre, Oncology Institute of Southern Switzerland, Bellinzona, SwitzerlandBackgroundVandetanib is the most largely used tyrosine kinase inhibitor (TKI) in patients with locally advanced and/or metastatic medullary thyroid cancer (MTC). Here, we conducted a systematic review on its efficacy and attempted to perform a meta-analysis adopting standardized RECIST criteria as end-points.MethodsThe terms “medullary thyroid” and “protein kinase inhibitor” (then including all TKIs) were searched in PubMed, ClinicalTrials.gov, and CENTRAL. Only original studies reporting the use of Vandetanib as single agent in MTC were included. The last search was performed on October 31, 2017 and registered in PROSPERO on December 12, 2017 (n = CRD42017081537).ResultsThe search revealed 487 articles, and, after removing duplicates, reading title and abstract, and screening the eligible papers, 10 studied were finally included. Two papers were randomized controlled trials and eight were observational longitudinal studies. No data were available for overall survival. No heterogeneity nor publication bias were recorded in the pooled rate of complete response (0.7%) and stable disease (47%). Mild to moderate heterogeneity were recorded in the pooled rate of other endpoints. Data of the studies did not allow to perform a meta-analysis of time-to-event outcomes.ConclusionVandetanib should be considered as a promising treatment in advanced MTC. However, data based on RECIST endpoints do not currently provide high-level evidence on its efficacy.http://journal.frontiersin.org/article/10.3389/fendo.2018.00224/fullmedullary thyroid carcinomatyrosine kinase inhibitorsvandetanibRECISTsystematic reviewmeta-analysis |
| spellingShingle | Pierpaolo Trimboli Marco Castellana Camilla Virili Francesco Giorgino Luca Giovanella Efficacy of Vandetanib in Treating Locally Advanced or Metastatic Medullary Thyroid Carcinoma According to RECIST Criteria: A Systematic Review and Meta-Analysis Frontiers in Endocrinology medullary thyroid carcinoma tyrosine kinase inhibitors vandetanib RECIST systematic review meta-analysis |
| title | Efficacy of Vandetanib in Treating Locally Advanced or Metastatic Medullary Thyroid Carcinoma According to RECIST Criteria: A Systematic Review and Meta-Analysis |
| title_full | Efficacy of Vandetanib in Treating Locally Advanced or Metastatic Medullary Thyroid Carcinoma According to RECIST Criteria: A Systematic Review and Meta-Analysis |
| title_fullStr | Efficacy of Vandetanib in Treating Locally Advanced or Metastatic Medullary Thyroid Carcinoma According to RECIST Criteria: A Systematic Review and Meta-Analysis |
| title_full_unstemmed | Efficacy of Vandetanib in Treating Locally Advanced or Metastatic Medullary Thyroid Carcinoma According to RECIST Criteria: A Systematic Review and Meta-Analysis |
| title_short | Efficacy of Vandetanib in Treating Locally Advanced or Metastatic Medullary Thyroid Carcinoma According to RECIST Criteria: A Systematic Review and Meta-Analysis |
| title_sort | efficacy of vandetanib in treating locally advanced or metastatic medullary thyroid carcinoma according to recist criteria a systematic review and meta analysis |
| topic | medullary thyroid carcinoma tyrosine kinase inhibitors vandetanib RECIST systematic review meta-analysis |
| url | http://journal.frontiersin.org/article/10.3389/fendo.2018.00224/full |
| work_keys_str_mv | AT pierpaolotrimboli efficacyofvandetanibintreatinglocallyadvancedormetastaticmedullarythyroidcarcinomaaccordingtorecistcriteriaasystematicreviewandmetaanalysis AT marcocastellana efficacyofvandetanibintreatinglocallyadvancedormetastaticmedullarythyroidcarcinomaaccordingtorecistcriteriaasystematicreviewandmetaanalysis AT camillavirili efficacyofvandetanibintreatinglocallyadvancedormetastaticmedullarythyroidcarcinomaaccordingtorecistcriteriaasystematicreviewandmetaanalysis AT francescogiorgino efficacyofvandetanibintreatinglocallyadvancedormetastaticmedullarythyroidcarcinomaaccordingtorecistcriteriaasystematicreviewandmetaanalysis AT lucagiovanella efficacyofvandetanibintreatinglocallyadvancedormetastaticmedullarythyroidcarcinomaaccordingtorecistcriteriaasystematicreviewandmetaanalysis |